when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Sep 8, 26AI will only revolutionize drug discovery and development if we play to its strengthsbiospace

Sep 8, 26Reeling from past failures, Parkinson's pipeline enters 'era of diversification'biospace

Sep 7, 26Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillyendpoints

Sep 5, 26Novartis, Ionis drug failure spurs questions about an emerging class of heart medicinesbiopharma dive

Sep 5, 26CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and moreendpoints

Sep 4, 26STAT+: Novartis’ experimental cardiovascular drug fails a pivotal studystat

Sep 4, 26Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trialfiercebiotech

Sep 4, 26This week in charts: China deals, stock flatlines and Lilly’s M&A spreebiopharma dive

Sep 3, 26An AI drug specialist zeroes in on rare forms of obesitybiopharma dive

Sep 3, 26Psilocybin proves promising in neuropathic pain mouse studyfiercebiotech

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 1, 26From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Applefiercebiotech

Sep 1, 26Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

Sep 1, 26Lilly’s 2026 dealmaking spreads the wealth among biotech venture investorsendpoints

Sep 1, 269 midsize drugmakers climb aboard Trump’s MFN trainbiospace

Sep 1, 26ArsenalBio sheds most of staff in pivot to in vivo CAR-Tfiercebiotech

Aug 31, 26Lilly adds to immune drug pipeline with $2.9B Merida buyoutbiopharma dive

Aug 31, 26Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026endpoints

Aug 31, 26Deal-hungry Lilly strikes up to $2.9B immuno play for Meridabiospace

Aug 31, 26ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trialfiercebiotech

Aug 31, 26Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodiesfiercebiotech

Aug 31, 26BMS’ neuro renaissance was built on back of Celgene mega-mergerbiospace

Aug 31, 26Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88Braps

Aug 28, 26Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drugendpoints

Aug 28, 26This week in charts: Biotech’s rebound is undeniablebiopharma dive

Aug 28, 26Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjarobiospace

Aug 28, 26STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and morestat

Aug 28, 26Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical datafiercebiotech

Aug 27, 26A year on from Big Pharma’s pull-back from the UK, has anything changed?fiercebiotech

Aug 27, 26Lilly's move to hide Phase 1 pipeline draws mixed reviewsendpoints

← prevpage 9 of 21next →